# EDGAR Filing Document

**Accession Number:** 0001787518
**File Stem:** 0001213900-23-005120
**Filing Date:** 2023-1
**Character Count:** 104432
**Document Hash:** f0e809f197d12bd9ce4b393c27be4c35
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-005120.hdr.sgml**: 20230125

**ACCESSION NUMBER**: 0001213900-23-005120

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20230119

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230125

**DATE AS OF CHANGE**: 20230125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Brilliant Acquisition Corp
- **CENTRAL INDEX KEY:** 0001787518
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39341
- **FILM NUMBER:** 23552634

**BUSINESS ADDRESS:**
- **STREET 1:** 99 DAN BA ROAD C-9
- **STREET 2:** PUTUO DISTRICT
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200062
- **BUSINESS PHONE:** 086-021-80125497

**MAIL ADDRESS:**
- **STREET 1:** 99 DAN BA ROAD C-9
- **STREET 2:** PUTUO DISTRICT
- **CITY:** SHANGHAI
- **STATE:** F4
- **ZIP:** 200062

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **January 19, 2023**

**BRILLIANT ACQUISITION CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **British Virgin Islands** | **001-39341** | **N/A** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**99 Dan Ba Road** **, C-9, Putuo District, Shanghai**, **Peoples Republic of China**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(86) 021-80125497**

**Not Applicable** (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on <br> which registered** |
| Units, each consisting of one Ordinary Share, one Right and one Redeemable Warrant | BRLIU | The Nasdaq Stock Market LLC |
| Ordinary Shares, no par value per share | BRLI | The Nasdaq Stock Market LLC |
| Rights, each right entitling the holder to 1/10 of one Ordinary Share | BRLIR | The Nasdaq Stock Market LLC |
| Warrants, each warrant exercisable for one Ordinary Share for $11.50 per share | BRLIW | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material definitive Agreement.**

*Amendment to Merger Agreement*

As previously reported, on February 22, 2022, Brilliant Acquisition Corporation, a British Virgin Islands company ("Brilliant"), entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement"), by and among Brilliant and Nukkleus Inc., a Delaware corporation ("Nukkleus"). Upon consummation of the transactions contemplated by the Merger Agreement, Nukkleus would become a Nasdaq-listed company ("PubCo") and the parent company of Brilliant. The transactions contemplated by the Merger Agreement, are hereinafter referred to as the "Business Combination."

On January 20, 2023, parties to the Merger Agreement entered into an Amendment No. 3 to the Merger Agreement (the "Amendment") solely to extend the Outside Closing Date (as defined in the Merger Agreement), to the later of (i) April 23, 2023, or, (ii) following the approval by Brilliant's shareholders of an extension of the life of the SPAC pursuant to Brilliant's organizational documents, to the date so approved, but not later than June 23, 2023.

The foregoing descriptions of the Merger Agreement and the Amendment are not complete and are subject to and qualified in their entirety by reference to the Merger Agreement and the Amendment, copies of which are filed with this Current Report on Form 8-K as Exhibits 2.1 and 2.2, respectively, and the terms of which are incorporated by reference herein.

*Promissory Note*

The disclosure contained in Item 2.03 is incorporated by reference in this Item 1.01.

**Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

Brilliant issued an unsecured promissory note dated January 20, 2023, in the aggregate principal amount of $21,350 (the "Note") to Nukkleus. The Note does not bear interest and matures upon closing of the Company's initial business combination. In the event that the Company does not consummate a business combination, the Note will be repaid only from amounts remaining outside of the Company's trust account, if any. The proceeds of the Note have been deposited in the Company's trust account in connection with extending the business combination completion window until February 23, 2023.

The foregoing description of the Note is qualified in its entirety by reference to the full text of the Note, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.

**Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On January 23, 2023, subsequent to the approval by its shareholders of the amended and restated articles of association (the "Amended Articles") of the Company, the Company filed the Amended Articles with the British Virgin Islands General Registry, effective the same day. The Amended Articles extend the date by which the Company has to consummate a business combination from January 23, 2023 to up to not later than April 23, 2023, extendable by the Company on a monthly basis without further shareholder approval upon deposit of $0.04 per public ordinary share of the Company (the "Top-up Amount").

Notwithstanding the Top-up Amount set forth in the Amended Articles, as disclosed in the Definitive Additional Materials on Form [DEFA14A](http://www.sec.gov/Archives/edgar/data/1787518/000121390023002978/ea171783-defa14a_brilliant.htm) filed by the Company with the Securities and Exchange Commission (the "SEC") on January 17, 2023, the Company undertook to increase the amount to be paid into the Trust Account for each monthly extension from $0.04 to $0.0525. Subsequently, the Company has committed to increase the amount to be paid into the Trust Account for any extension from February 23, 2023 to March 23, 2023 and from March 23, 2023 April 23, 2023 to $0.08 per ordinary share outstanding.

**Item 5.07. Submissions of Matters to a Vote of Security Holders.**

The Company held the special meeting of shareholders of the Company (the "Special Meeting") on January 19, 2023 at 10:00 a.m. Eastern Time. The Special Meeting was held via teleconference. Summarized below are the results of the matters submitted to a vote at the Special Meeting.

---

| | | | |
|:---|:---|:---|:---|
| **Matter** | **For** | **Against** | **Abstain** |
| Proposal 1 – The Extension Amendment Proposal - A proposal to amend the Company's currently adopted amended and restated articles of association (the "Current Articles"), to extend the date by which the Company has to consummate a business combination from January 23, 2023 to up to not later than April 23, 2023 by deleting articles 18.6(A) and 18(B) of the Current Articles in their entirety, and replacing them with new articles 18.6(A) and 18.6(B), respectively, as set forth in Annex A to the Company's proxy statement. | 1630091 | 30 | 2000 |
| Proposal 2 – The Amended Articles Proposal - A proposal to adopt an amended and restated articles of association of the Company reflecting the amendments to the Current Articles set out in Proposal 1. | 1630091 | 30 | 2000 |

---

Proposal 1 and Proposal 2 were approved by the Company's shareholders.

**Item 7.01 Regulation FD Disclosure.**

The Company's shareholders elected to redeem an aggregate of 159,203 shares in connection with the Special Meeting. Following such redemptions and the deposit of the contribution described above, the amount of funds remaining in the trust account is approximately $4.4 million. Accordingly, following such redemptions and the deposit of the contribution of $0.525 per outstanding ordinary share, the Company has 1,816,733 ordinary shares issued and outstanding (1,411,000 of which are shares held by our initial shareholders and are not subject to redemption) and the pro rata portion of the funds available in the trust account is approximately $10.77 per public share.

On January 24, 2023, the Company issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that the Company has extended the period of time it will have to consummate its initial business combination by a further one month, or until February 23, 2023, and related matters.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Additional Information and Where to Find It**

This Current Report relates to a proposed business combination among Nukkleus, Brilliant and Merger Sub in which Merger Sub would merge into Brilliant. In connection with the proposed transaction, Nukkleus has filed with the SEC a registration statement on Form S-4 that includes a proxy statement of Nukkleus and that also constitutes a prospectus of Nukkleus with respect to the PubCo Shares to be issued in the proposed transaction (the "proxy statement/prospectus"). The definitive proxy statement/prospectus (if and when available) will be delivered to Nukkleus's stockholders. Each of Nukkleus and Brilliant may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF NUKKLEUS AND BRILLIANT ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders may obtain free copies of the proxy statement/prospectus (if and when available) and other documents that are filed or will be filed with the SEC by Brilliant or Nukkleus through the website maintained by the SEC at www.sec.gov. Stockholders of Nukkleus will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Nukkleus, Inc., 525 Washington Boulevard, Jersey City, New Jersey 07310. Shareholders of Brilliant will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Brilliant Acquisition Corporation, 99 Dan Ba Road, C-9, Putuo District, Shanghai, Peoples Republic of China.

**Participants in the Solicitation**

Brilliant and its directors and executive officers are participants in the solicitation of proxies from the shareholders of Brilliant in respect of the proposed transaction. Information about Brilliant's directors and executive officers and their ownership of Brilliant's ordinary shares is set forth in Brilliant's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Nukkleus and its directors and executive officers are participants in the solicitation of proxies from the shareholders of Nukkleus in respect of the proposed transaction. Information about Nukkleus's directors and executive officers and their ownership of Nukkleus common stock is set forth in Nukkleus's Annual Report on Form 10-K for the year ended September 30, 2021, initially filed with the SEC on December 29, 2021, as amended to date. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described above.

**Cautionary Note Regarding Forward-Looking Statements**

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the proposed business combination may not be completed in a timely manner or at all, which may adversely affect the price of Nukkleus and/or Brilliant securities; (ii) the risk that the proposed business combination may not be completed by Brilliant's business combination deadline and the potential failure to obtain an extension of the business combination deadline if sought by Brilliant; (iii) the failure to satisfy the conditions to the consummation of the proposed business combination, including the approval of the proposed business combination by the stockholders of Nukkleus and/or Brilliant, the satisfaction of the minimum trust account amount following redemptions by Brilliant's public shareholders and the receipt of certain governmental and regulatory approvals; (iv) the effect of the announcement or pendency of the proposed business combination on Nukkleus's business relationships, performance, and business generally; (v) risks that the proposed business combination disrupts current plans of Nukkleus and potential difficulties in Nukkleus employee retention as a result of the proposed business combination; (vi) the outcome of any legal proceedings that may be instituted against Nukkleus or Brilliant related to the agreement and plan of merger or the proposed business combination; (vii) the ability to maintain the listing of Brilliant's securities on the Nasdaq Stock Market; (viii) the price of Nukkleus's and/or Brilliant's securities, including volatility resulting from changes in the competitive and highly regulated industries in which Nukkleus and Brilliant plan to operate, variations in performance across competitors, changes in laws and regulations affecting Nukkleus's business and changes in the combined capital structure; and (ix) the ability to implement business plans, forecasts, and other expectations after the completion of the proposed business combination, and identify and realize additional opportunities. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the proxy statement/prospectus contained in Nukkleus's Form S-4 registration statement described below, including those under "Risk Factors" therein, the Annual Report on Form 10-K for Nukkleus and Brilliant, Quarterly Reports on Form 10-Q for Nukkleus and Brilliant and other documents filed by Nukkleus and/or Brilliant from time to time with the U.S. Securities and Exchange Commission (the "SEC"). These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Nukkleus and Brilliant assume no obligation and, except as required by law, do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Nukkleus nor Brilliant gives any assurance that either Nukkleus or Brilliant will achieve its expectations.

**No Offer or Solicitation**

This communication is not intended to and will not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any vote or approval and is not a substitute for the proxy statement/prospectus or any other document that Brilliant or Nukkleus may file with the SEC or send to Nukkleus's and/or Brilliant's shareholders in connection with the proposed transaction. No offer of securities will be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.

**Item 9.01. Financial Statements and Exhibits**

(c) Exhibits:

---

| | |
|:---|:---|
| Exhibit No. | Description |
| 2.1† | [Agreement and Plan of Merger, dated as of February 22, 2022, by and among Nukkleus Inc. and Brilliant Acquisition Corporation (incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 23, 2022).](http://www.sec.gov/Archives/edgar/data/1787518/000121390022008813/ea155992ex2-1_brilliantacq.htm) |
| 2.2 | [Amendment No 3. to Agreement and Plan of Merger, dated as of January 20, 2023, by and among Nukkleus Inc. and Brilliant Acquisition Corporation.](ea172192ex2-2_brilliant.htm) |
| 3.1 | [Amended and Restated Articles of Association](ea172192ex3-1_brilliant.htm) |
| 10.1 | [Promissory Note, dated January 20, 2023](ea172192ex10-1_brilliant.htm) |
| 99.1 | [Press Release, dated January 24, 2023](ea172192ex99-1_brilliant.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

† Certain of the exhibits and schedules to this exhibit have been
omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits
and schedules to the SEC upon its request.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **BRILLIANT ACQUISITION CORPORATION** | **BRILLIANT ACQUISITION CORPORATION** | **BRILLIANT ACQUISITION CORPORATION** |
|  | By: | /s/ Dr. Peng Jiang | /s/ Dr. Peng Jiang |
|  |  | Name: | Dr. Peng Jiang |
|  |  | Title: | Chief Executive Officer |
| Dated: January 25, 2023 |  |  |  |

---

## Exhibit 2.2

**Exhibit 2.2**

**AMENDMENT NO. 3 TO AGREEMENT AND PLAN OF MERGER**

January <u>20</u>, 2023

THIS AMENDMENT NO. 3 to the Agreement and Plan of Merger (as amended prior to the date hereof, the "<u>Merger Agreement</u>"), dated as of February 22, 2022, by and among Nukkleus Inc., a Delaware corporation (the "<u>Company</u>"), Brilliant Acquisition Corporation, a British Virgin Islands company (the "<u>SPAC</u>") and NB Merger Sub, Inc., a British Virgin Islands company, is effective as of this <u>20th</u> day of January, 2023 (this "<u>Amendment</u>"). Capitalized terms used herein but not defined herein shall have the meanings ascribed to them in the Merger Agreement.

In consideration of the mutual promises contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Amendment.** The first sentence of Section 12.1(a) of the Merger Agreement is hereby amended as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In the event that the Closing of the transactions contemplated hereunder has not occurred by the later of (i) April 23, 2023, or, (ii) following the approval by the SPAC shareholders of the extension of the life of the SPAC pursuant to the SPAC's Organizational Documents, to the date so approved, but not later than June 23, 2023 (such later date, the "<u>Outside Closing Date</u>"), and no material breach of this Agreement by the party seeking to terminate this Agreement shall have occurred or have been made (as provided in Section 12.2 hereof), the SPAC or the Company, as the case may be, shall have the right, at its sole option, to terminate this Agreement without liability to the other side.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **No Other Amendments, etc.** Except as provided in this Amendment, the Merger Agreement shall remain unmodified and in full force and effect, and the execution of this Amendment is not a waiver by the Company or the SPAC of any of the terms or provisions of the Merger Agreement and each party reserves any and all other rights and remedies available to it under the Merger Agreement. All reference in and to the Merger Agreement (including any annexes, exhibits or schedules thereto) shall be deemed to be references to the Merger Agreement as amended by this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Governing Law**. This Amendment and the legal relations among the Parties with respect to this Amendment will be governed by and construed in accordance with the provisions contained in <u>Section 13.7</u> of the Merger Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Counterparts.** This Amendment may be executed by signatures exchanged via facsimile or other electronic means and in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[*Signature page follows*]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written.

---

| | |
|:---|:---|
| SPAC: | SPAC: |
| **BRILLIANT ACQUISITION CORPORATION** | **BRILLIANT ACQUISITION CORPORATION** |
| By: | /s/ Peng Jiang |
|  | Name: Peng Jiang |
|  | Title: CEO |

---

[Signature Page to Amendment No. 3 to Merger Agreement]

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the day and year first above written.

---

| | |
|:---|:---|
| Company: | Company: |
| **NUKKLEUS INC.** | **NUKKLEUS INC.** |
| By: | /s/ Emil Assentato |
|  | Name: Emil Assentato |
|  | Title: CEO |

---

[Signature Page to Amendment No. 3 to Merger Agreement]

## Exhibit 3.1

**Exhibit 3.1**

TERRITORY OF THE BRITISH VIRGIN

ISLANDS THE BVI BUSINESS

COMPANIES ACT, 2004 AMENDED AND

RESTATED

ARTICLES OF

ASSOCIATION OF

**Brilliant Acquisition Corporation**

A COMPANY LIMITED BY SHARES

Amended and restated by a Resolution of Members passed on 19 January 2023 and filed on 23 January 2023

1. REGISTERED SHARES

1.1. Every Member is entitled to a certificate signed by a director of the Company or under the Seal specifying
the number of Shares held by him and the signature of a Director.

1.2. Any Member receiving a certificate shall indemnify and hold the Company and its Directors and officers
harmless from any loss or liability which it or they may incur by reason of any wrongful or fraudulent use or representation made by any
person by virtue of the possession thereof. If a certificate for Shares is worn out or lost it may be renewed on production of the worn
out certificate or on satisfactory proof of its loss together with such indemnity as may be required by a Resolution of Directors.

1.3. If several Eligible Persons are registered as joint holders of any Shares, any one of such Eligible Persons
may give an effectual receipt for any Distribution.

2. SHARES

2.1. Subject to the provisions, if any, in the Memorandum (and to any direction that may be given by the Company
in general meeting), the Act and, where applicable, the rules of the Designated Stock Exchange and/or any competent regulatory authority,
and without prejudice to any rights attached to any existing Shares, the Directors may allot, issue, grant options over or otherwise dispose
of Shares (including fractions of a Share) with or without preferred, deferred or other rights or restrictions, whether in regard to Dividend
or other distribution, voting, return of capital or otherwise and to such persons, at such times and on such other terms as they think
proper, and may also (subject to the Act and the Articles) vary such rights.

2.2. The Company may issue Securities to Eligible Persons conferring the right upon the holders thereof to
subscribe for, purchase or receive any class of Shares or other securities in the Company on such terms as the Directors may from time
to time determine.

2.3. Section 46 of the Act does not apply to the Company.

2.4. The Company may issue units of Securities in the Company, which may be comprised of whole or fractional
Shares, rights, options, warrants or convertible securities or securities of similar nature conferring the right upon the holders thereof
to subscribe for, purchase or receive any class of Shares or other Securities in the Company, upon such terms as the Directors may from
time to time determine. The Securities comprising any such units which are issued pursuant to the IPO can only be traded separately from
one another on the 90th day following the date of the prospectus relating to the IPO unless the representative of the Underwriters in
the IPO determines that an earlier date is acceptable, subject to the Company having filed a current report on Form 8-K with the SEC and
a press release announcing when such separate trading will begin. Prior to such date, the units can be traded, but the securities comprising
such units cannot be traded separately from one another.

2.5. No Shares may be issued for a consideration other than money, unless a Resolution of Directors has been
passed stating:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the amount to be credited for the issue of the Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) their determination of the reasonable present cash value of the non-money consideration for the issue;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) that, in their opinion, the present cash value of the non-money consideration for the issue is not less
than the amount to be credited for the issue of the Shares.

2.6. The Company shall keep a Register of Members, in compliance with section 41 of the Act, containing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the names and addresses of the persons who hold Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the number of each class and series of Shares held by each Member;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the date on which the name of each Member was entered in the Register of Members; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the date on which any Eligible Person ceased to be a Member.

2.7. The Register of Members may be in any such form as the Directors may approve, but if it is in magnetic,
electronic or other data storage form, the Company must be able to produce legible evidence of its contents. Until the Directors otherwise
determine, the magnetic, electronic or other data storage form shall be the original share register.

2.8. A Share is deemed to be issued when the name of the Member is entered in the Register of Members.

3. FORFEITURE

3.1. Shares that are not fully paid on issue are subject to the forfeiture provisions set forth in this Regulation
and for this purpose Shares and Securities issued for a promissory note or a contract for future services are deemed to be not fully paid.

3.2. A written notice ()"**Call Notice**") of call specifying the date for payment to be made
shall be served on the Member who defaults in making payment in respect of the Shares and Securities.

3.3. The Call Notice referred to in Regulation 3.2 shall name a further date not earlier than the expiration
of 14 days from the date of service of the Call Notice on or before which the payment required by the Call Notice is to be made and shall
contain a statement that in the event of non-payment at or before the time named in the Call Notice, the Shares or Securities, or any
of them, in respect of which payment is not made will be liable to be forfeited.

3.4. Where a Call Notice has been issued pursuant to Regulation 3.2 and the requirements of the Call Notice
have not been complied with, the Directors may, at any time before tender of payment, forfeit and cancel the Shares and Securities to
which the Call Notice relates.

3.5. The Company is under no obligation to refund any moneys to the Member whose Shares or Securities have
been cancelled pursuant to Regulation 3.4 and that Member shall be discharged from any further obligation to the Company.

4. TRANSFER OF SHARES

4.1. Subject to the Memorandum shares may be transferred by a written instrument of transfer signed by the
transferor and containing the name and address of the transferee, which shall be sent to the Company for registration, provided that such
transfer also complies with applicable rules of the SEC and federal and state securities laws of the United States. If the Shares in question
were issued in conjunction with rights, options or warrants issued on terms that one cannot be transferred without the other, the Directors
shall refuse to register the transfer of any such Share without evidence satisfactory to them of the like transfer of such option or warrant.

4.2. Shares held by the Founders shall not be transferred (except (1) to any persons (including their affiliates
and shareholders) participating in the private placement of the private units, officers, directors, shareholders, employees and members
of the Sponsor and its affiliates, (2) amongst initial holders or to the Company's officers, directors and employees, (3) if
a holder is an entity, as a distribution to its partners, shareholders or members upon its liquidation, (4) by bona fide gift to a member
of the holder's immediate family or to a trust, the beneficiary of which is a holder or a member of a holder's immediate family,
for estate planning purposes, (5) by virtue of the laws of descent and distribution upon death, (6) pursuant to a qualified domestic relations
order, (7) by certain pledges to secure obligations incurred in connection with purchases of the Company's securities, (8) by private
sales at prices no greater than the price at which the applicable securities were originally purchased or (9) to the Company for no value
for cancellation in connection with the consummation of the Company's initial Business Combination, in each case (except for clause
9) where the transferee agrees to the terms of the insider letter and by the same agreements entered into by the Sponsor with respect
to such securities (including provisions relating to voting, the trust account and liquidation distributions described in the prospectus
issued by the Company in respect of the IPO))) until the earlier of (i) one year after the date of the consummation of the initial Business
Combination; or (ii) the date on which the closing price of the Ordinary Shares equals or exceeds $12.50 per share (as adjusted for share
splits, share dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period following the
six month anniversary of the consummation of our initial Business Combination, or earlier, in either case, if, subsequent to the initial
Business Combination, the Company consummates a subsequent liquidation, merger, share exchange or other similar transaction which results
in all of the Members having the right to exchange their Ordinary Shares for cash, securities or other property.

4.3. In addition to the above, the instrument of transfer of any Share shall be in writing in the usual or
common form or in a form prescribed by the Designated Stock Exchange or in any other form approved by the officers of the Company and
shall be executed by or on behalf of the transferor (and if the Directors so require, signed by or on behalf of the transferee) and may
be under hand or, if the transferor or transferee is a clearing house or its nominee(s), by hand or by machine imprinted signature or
by such other manner of execution as the Directors may approve from time to time.

4.4. The transfer of a Share is effective when the name of the transferee is entered on the share register.
The transferor shall be deemed to remain the holder of a Share until the name of the transferee is entered in the Register of Members.

4.5. If the Directors of the Company are satisfied that an instrument of transfer relating to Shares has been
signed but that the instrument has been lost or destroyed, they may resolve by Resolution of Directors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) to accept such evidence of the transfer of Shares as they consider appropriate; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) that the transferee's name should be entered in the Register of Members notwithstanding the absence
of the instrument of transfer.

4.6. Subject to the Memorandum, the personal representative of a deceased Member may transfer a Share even
though the personal representative is not a Member at the time of the transfer.

5. DISTRIBUTIONS

5.1. The Company may by Resolution of Directors, authorize a distribution at a time and of an amount they think
fit if they are satisfied, on reasonable grounds, that, immediately after the distribution, the value of the Company's assets will
exceed its liabilities and the Company will be able to pay its debts as and when they fall due.

5.2. Dividends may be paid in money, shares, or other property.

5.3. The Company may, by Resolution of Directors, from time to time pay to the Members such interim dividends
as appear to the Directors to be justified by the profits of the Company, provided always that they are satisfied, on reasonable grounds,
that, immediately after the distribution, the value of the Company's assets will exceed its liabilities and the Company will be
able to pay its debts as and when they fall due.

5.4. Notice in writing of any dividend that may have been declared shall be given to each Member in accordance
with Regulation 20 and all dividends unclaimed for three years after such notice has been given to a Member may be forfeited by Resolution
of Directors for the benefit of the Company.

5.5. No dividend shall bear interest as against the Company.

6. REDEMPTION OF SHARES AND TREASURY SHARES

6.1. Subject to these Articles, the Company may purchase, redeem or otherwise acquire and hold its own Shares
save that the Company may not purchase, redeem or otherwise acquire its own Shares without the consent of the Member whose Shares are
to be purchased, redeemed or otherwise acquired unless the Company is permitted by the Act or any other provision in the Memorandum or
Articles to purchase, redeem or otherwise acquire the Shares without such consent.

6.2. The purchase redemption or other acquisition by the Company of its own Shares is deemed not to be a distribution
where:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The Company purchases, redeems or otherwise acquires the Shares pursuant to a right of a Member to have
his Shares redeemed or to have his shares exchanged for money or other property of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company purchases, redeems or otherwise acquires the Shares by virtue of the provisions of section
176of the Act.

6.3. Sections 60, 61 and 62 of the Act shall not apply to the Company.

6.4. Shares that the Company purchases, redeems or otherwise acquires pursuant to this Regulation may be cancelled
or held as Treasury Shares except to the extent that such Shares are in excess of 50 percent of the issued Shares in which case they shall
be cancelled but they shall be available for reissue.

6.5. All rights and obligations attaching to a Treasury Share are suspended and shall not be exercised by the
Company while it holds the Share as a Treasury Share.

6.6. Treasury Shares may be disposed of by the Company on such terms and conditions (not otherwise inconsistent
with the Memorandum and Articles) as the Company may by Resolution of Directors determine.

6.7. Where Shares are held by another body corporate of which the Company holds, directly or indirectly, shares
having more than 50 per cent of the votes in the election of directors of the other body corporate, all rights and obligations attaching
to the Shares held by the other body corporate are suspended and shall not be exercised by the other body corporate.

7. MEETINGS AND CONSENTS OF MEMBERS

7.1. Any director of the Company may convene meetings of the Members at such times and in such manner and places
within or outside the British Virgin Islands as the director considers necessary or desirable.

7.2. Upon the written request of the Members entitled to exercise thirty per cent (30%) or more of the voting
rights in respect of the matter for which the meeting is requested the Directors shall convene a meeting of Members.

7.3. The Director convening a meeting shall give at least ten (10) days' written notice of a meeting
of Members to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) those Members whose names on the date the notice is given appear as Members in the Register of Members
and are entitled to vote at the meeting; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the other Directors.

7.4. The director convening a meeting of Members may fix as the record date for determining those Members that
are entitled to vote at the meeting the date notice is given of the meeting, or such other date as may be specified in the notice, being
a date not earlier than the date of the notice.

7.5. A meeting of Members held in contravention of the requirement to give notice is valid if Members holding
at least 90 per cent of the total voting rights on all the matters to be considered at the meeting have waived notice of the meeting and,
for this purpose, the presence of a Member at the meeting shall constitute waiver in relation to all the Shares which that Member holds.

7.6. The inadvertent failure of a director who convenes a meeting to give notice of a meeting to a Member or
another director, or the fact that a Member or another director has not received notice, does not invalidate the meeting.

7.7. A Member may be represented at a meeting of Members by a proxy who may speak and vote on behalf of the
Member.

7.8. The instrument appointing a proxy shall be produced at the place designated for the meeting before the
time for holding the meeting at which the person named in such instrument proposes to vote.

7.9. The instrument appointing a proxy shall be in substantially the following form or such other form as the
chairman of the meeting shall accept as properly evidencing the wishes of the Member appointing the proxy.

---

| |
|:---|
| ***To: [●]*** |
| *I/We, being a Member of the above Company HEREBY APPOINT ...................... of ..............................or failing him ................ of ................................. to be my/our proxy to vote for me/us at the meeting of Members to be held on the ............... day of ....., 20.... and at any adjournment thereof.* |
| *(Any restrictions on voting to be inserted here.) Signed this ...... day of ............., 20....* |
| *.............................................* |
| *Member* |

---

7.10. The following applies where Shares are jointly owned:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) if two or more persons hold Shares jointly each of them may be present in person or by proxy at a meeting
of Members and may speak as a Member;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) if only one of the joint owners is present in person or by proxy he may vote on behalf of all joint owners;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) if two or more of the joint owners are present in person or by proxy they must vote as one and in the
event of disagreement between any of the joint owners of Shares then the vote of the joint owner whose name appears first (or earliest)
in the Register of Members in respect of the relevant Shares shall be recorded as the vote attributable to the Shares.

7.11. A Member shall be deemed to be present at a meeting of Members if he participates by telephone or other
electronic means and all Members participating in the meeting are able to hear each other.

7.12. A meeting of Members is duly constituted if, at the commencement of the meeting, there are present in
person or by proxy Members representing not less than thirty per cent (30%) of the votes of the Shares entitled to vote on Resolutions
of Members to be considered at the meeting. If the Company has two or more classes of shares, a meeting may be quorate for some purposes
and not for others. A quorum may comprise a single Member or proxy and then such person may pass a Resolution of Members and a certificate
signed by such person accompanied where such person holds a proxy by a copy of the proxy instrument shall constitute a valid Resolution
of Members.

7.13. If within two hours from the time appointed for the meeting a quorum is not present, the meeting, if convened
upon the requisition of Members, shall be dissolved; in any other case it shall stand adjourned to the next business day in the jurisdiction
in which the meeting was to have been held at the same time and place, and if at the adjourned meeting there are present within one hour
from the time appointed for the meeting in person or by proxy not less than one third of the votes of the Shares or each class or series
of Shares entitled to vote on the matters to be considered by the meeting, those present shall constitute a quorum but otherwise the meeting
shall be dissolved.

7.14. At every meeting of Members, the chairman of the Board shall preside as chairman of the meeting. If there
is no chairman of the Board or if the chairman of the Board is not present at the meeting, the Members present shall choose one of their
number to be the chairman. If the Members are unable to choose a chairman for any reason, then the person representing the greatest number
of voting Shares present in person or by proxy at the meeting shall preside as chairman failing which the oldest individual Member or
representative of a Member present shall take the chair.

7.15. The chairman may, with the consent of the meeting, adjourn any meeting from time to time, and from place
to place.

7.16. At any meeting of the Members the chairman is responsible for deciding in such manner as he considers
appropriate whether any resolution proposed has been carried or not and the result of his decision shall be announced to the meeting and
recorded in the minutes of the meeting. If the chairman has any doubt as to the outcome of the vote on a proposed resolution, he shall
cause a poll to be taken of all votes cast upon such resolution. If the chairman fails to take a poll then any Member present in person
or by proxy who disputes the announcement by the chairman of the result of any vote may immediately following such announcement demand
that a poll be taken and the chairman shall cause a poll to be taken. If a poll is taken at any meeting, the result shall be announced
to the meeting and recorded in the minutes of the meeting.

7.17. Subject to the specific provisions contained in this Regulation for the appointment of representatives
of Members other than individuals the right of any individual to speak for or represent a Member shall be determined by the law of the
jurisdiction where, and by the documents by which, the Member is constituted or derives its existence. In case of doubt, the Directors
may in good faith seek legal advice and unless and until a court of competent jurisdiction shall otherwise rule, the Directors may rely
and act upon such advice without incurring any liability to any Member or the Company.

7.18. Any Member, other than an individual, may by resolution of its directors or other governing body, authorize
such individual as it thinks fit to act as its representative at any meeting of Members or of any class of Members, and the individual
so authorized shall be entitled to exercise the same rights on behalf of the Member which he represents as that Member could exercise
if it were an individual.

7.19. The chairman of any meeting at which a vote is cast by proxy or on behalf of any Member other than an
individual may at the meeting but not thereafter call for a notarially certified copy of such proxy or authority which shall be produced
within 7 days of being so requested or the votes cast by such proxy or on behalf of such Member shall be disregarded.

7.20. Directors of the Company may attend and speak at any meeting of Members and at any separate meeting of
the holders of any class or series of Shares.

7.21. An action that may be taken by the Members at a meeting may also be taken by a Resolution of Members consented
to in writing, without the need for any prior notice. If any Resolution of Members is adopted otherwise than by the unanimous written
consent of all Members, a copy of such resolution shall forthwith be sent to all Members not consenting to, or not having signed, such
resolution. The consent may be in the form of counterparts, each counterpart being signed by one or more Members. If the consent is in
one or more counterparts, and the counterparts bear different dates, then the resolution shall take effect on the earliest date upon which
Eligible Persons holding a sufficient number of votes of Shares to constitute a Resolution of Members have consented to the resolution
by signed counterparts.

8. UNTRACEABLE MEMBERS

8.1. Where any Member is untraceable, the Company may sell any of their Shares provided that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) no less than 3 checks for any sums payable in cash to such Member have remained uncashed for a period
of 12 years from the date of issue of the check;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Company not having during that time or before the expiry of the three-month period referred to in
(c) below received any indication of the existence of the Member or person entitled to such shares by death, bankruptcy or operation of
law; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) upon expiration of the 12-year period, an advertisement has been published in newspapers, giving notice
of the Company's intention to sell those Shares, and a period of three months or such shorter period has elapsed since the date
of such advertisement.

then, the net proceeds of any such sale shall be held in the Company, and the net proceeds shall be accounted as a debt due to that untraceable Member for an amount equal to such net proceeds.

9. DIRECTORS

9.1. The Director or Directors shall be elected by Resolution of Members or by Resolution of Directors for
such term as the Members or Directors shall determine.

9.2. No person shall be appointed as a director of the Company unless he has consented in writing to act as
a director.

9.3. Subject to Regulation 9.1, the minimum number of Directors shall be one (1) and there shall be no maximum
number of Directors.

9.4. Each Director holds office for the term, if any, fixed by the Resolution of Members or Resolution of Directors
appointing him, or until his earlier death, resignation or removal. If no term is fixed on the appointment of a Director, the Director
shall serve indefinitely until his earlier death, resignation or removal.

9.5. A director may be removed from office with or without cause by:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) a Resolution of Members called for the purposes of removing the director or for purposes including the
removal of the director or by a written resolution passed by a least seventy five per cent of the Members of the Company entitled to vote,
provided that no director appointed from the closing of the IPO until consummation of the initial Business Combination may be removed
by a Resolution of Members; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) a Resolution of Directors.

9.6. A Director may resign his office by giving written notice of his resignation to the Company and the resignation
has effect from the date the notice is received by the Company at the office of its registered agent or from such later date as may be
specified in the notice. A director shall resign forthwith as a Director if he is, or becomes, disqualified from acting as a director
under the Act.

9.7. The Directors may at any time appoint any person to be a Director either to fill a vacancy or as an addition
to the existing Directors. Where the Directors appoint a person as Director to fill a vacancy, the term shall not exceed the term that
remained when the Director being replaced ceased to hold office.

9.8. A vacancy in relation to Directors occurs if a Director dies or otherwise ceases to hold office prior
to the expiration of his term of office.

9.9. The Company shall keep a register of directors complying with the Act containing:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the names and addresses of the persons who are Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the date on which each person whose name is entered in the register of Directors was appointed as a Director
of the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the date on which each person named as a Director ceased to be a Director of the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) such other information as may be prescribed by the Act.

9.10. The register of Directors may be kept in any such form as the Directors may approve, but if it is in magnetic,
electronic or other data storage form, the Company must be able to produce legible evidence of its contents. Until a Resolution of Directors
determining otherwise is passed, the magnetic, electronic or other data storage shall be the original register of Directors.

9.11. A Director is not required to hold a Share as a qualification to office.

10. REMUNERATION OF DIRECTORS

10.1. The remuneration to be paid to the Directors, if any, shall be such remuneration as the Directors shall
determine, provided that no remuneration shall be paid to any Director prior to the consummation of a Business Combination. The Directors
shall also, whether prior to or after the consummation of a Business Combination, be entitled to be paid all travelling, hotel and other
expenses properly incurred by them in connection with their attendance at meetings of Directors or committees of Directors, or general
meetings of the Company, or separate meetings of the holders of any class of Shares or debentures of the Company, or otherwise in connection
with the business of the Company or the discharge of their duties as a Director, or to receive a fixed allowance in respect thereof as
may be determined by the Directors, or a combination partly of one such method and partly the other.

10.2. The Directors may by resolution approve additional remuneration to any Director for any services which
in the opinion of the Directors go beyond his ordinary routine work as a Director. Any fees paid to a Director who is also counsel, attorney
or solicitor to the Company (collectively an "**Advisor** "), or otherwise serves in his capacity as an Advisor shall be
separately remunerated for services provided as an Advisor in addition to his remuneration as a Director.

11. POWERS OF DIRECTORS

11.1. The business and affairs of the Company shall be managed by, or under the direction or supervision of,
the Directors. The Directors have all the powers necessary for managing, and for directing and supervising, the business and affairs of
the Company. The Directors may pay all expenses incurred preliminary to and in connection with the incorporation of the Company and may
exercise all such powers of the Company as are not by the Act or by the Memorandum or the Articles required to be exercised by the Members.

11.2. If the Company is the wholly owned subsidiary of a holding company, a director of the Company may, when
exercising powers or performing duties as a director, act in a manner which he believes is in the best interests of the holding company
even though it may not be in the best interests of the Company.

11.3. If the Company is a subsidiary, but not a wholly owned subsidiary, of a holding company, and the Members
other than the holding company agree in advance, a director of the Company may, when exercising powers or performing duties as a director
in connection with the carrying out of the joint venture, act in a manner which he believes is in the best interests of a Member or some
Members even though it may not be in the best interests of the Company.

11.4. If the Company is carrying out a joint venture between Members, a director of the Company may, when exercising
powers or performing duties as a director, act in a manner which he believes is in the best interests of the holding company even though
it may not be in the best interests of the Company.

11.5. Each Director shall exercise his powers for a proper purpose and shall not act or agree to the Company
acting in a manner that contravenes the Memorandum, the Articles or the Act. Each Director, in exercising his powers or performing his
duties, shall act honestly and in good faith in what the Director believes to be the best interests of the Company.

11.6. The Directors may by Resolution of Directors exercise all the powers of the Company to incur indebtedness,
liabilities or obligations and to secure indebtedness, liabilities or obligations whether of the Company or of any third party.

11.7. All cheques, promissory notes, drafts, bills of exchange and other negotiable instruments and all receipts
for moneys paid to the Company shall be signed, drawn, accepted, endorsed or otherwise executed, as the case may be, in such manner as
shall from time to time be determined by Resolution of Directors.

11.8. Section 175 of the Act shall not apply to the Company.

12. PROCEEDINGS OF DIRECTORS

12.1. Any one director of the Company may call a meeting of the Directors by sending a written notice to all
other Directors.

12.2. The Directors or any committee thereof may meet at such times
and in such manner and places within or outside the British Virgin Islands as the notice calling the meeting provides.

12.3. A Director is deemed to be present at a meeting of Directors if he participates by telephone or other
electronic means and all Directors participating in the meeting are able to hear each other.

12.4. A Director shall be given not less than three days' notice of meetings of Directors, but a meeting
of Directors held without three days' notice having been given to all Directors shall be valid if all the Directors entitled to
vote at the meeting waive notice of the meeting, and for this purpose the presence of a Director at a meeting shall constitute waiver
by that director. The inadvertent failure to give notice of a meeting to a Director, or the fact that a Director has not received the
notice, does not invalidate the meeting.

12.5. A meeting of Directors is duly constituted for all purposes if at the commencement of the meeting there
are present in person not less than one-half of the total number of Directors, unless there are only two Directors in which case the quorum
is two.

12.6. If the Company has only one Director the provisions herein contained for meetings of Directors do not
apply and such sole Director has full power to represent and act for the Company in all matters as are not by the Act, the Memorandum
or the Articles required to be exercised by the Members. In lieu of minutes of a meeting the sole Director shall record in writing and
sign a note or memorandum of all matters requiring a Resolution of Directors. Such a note or memorandum constitutes sufficient evidence
of such resolution for all purposes.

12.7. At meetings of Directors at which the chairman of the Board is present, he shall preside as chairman of
the meeting. If there is no chairman of the Board or if the chairman of the Board is not present, the Directors present shall choose one
of their number to be chairman of the meeting. If the Directors are unable to choose a chairman for any reason, then the longest standing
Director present shall take the chair.

12.8. An action that may be taken by the Directors or a committee of directors at a meeting may also be taken
by a Resolution of Directors or a resolution of a committee of Directors consented to in writing by all Directors or by all members of
the committee, as the case may be, without the need for any notice. The consent may be in the form of counterparts each counterpart being
signed by one or more Directors. If the consent is in one or more counterparts, and the counterparts bear different dates, then the resolution
shall take effect on the date upon which the last director has consented to the resolution by signed counterparts.

13. COMMITTEES

13.1. The Directors may, by Resolution of Directors, designate one or more committees, each consisting of one
or more Directors, and delegate one or more of their powers, including the power to affix the Seal, to the committee.

13.2. The Directors have no power to delegate to a committee of directors any of the following powers:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) to amend the Memorandum or the Articles:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) to designate committees of directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) to delegate powers to a committee of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) to appoint Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) to appoint an agent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) to approve a plan of merger, consolidation or arrangement; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) to make a declaration of solvency or to approve a liquidation plan.

13.3. Regulations 13.2(b) and 13.2(c) do not prevent a committee of Directors, where authorized by the Resolution
of Directors appointing such committee or by a subsequent Resolution of Directors, from appointing a sub-committee and delegating powers
exercisable by the committee to the sub-committee.

13.4. The meetings and proceedings of each committee of Directors consisting of 2 or more Directors shall be
governed *mutatis mutandis* by the provisions of the Articles regulating the proceedings of Directors so far as the same are not
superseded by any provisions in the Resolution of Directors establishing the committee.

14. OFFICERS AND AGENTS

14.1. The Company may by Resolution of Directors appoint officers of the Company at such times as may be considered
necessary or expedient. Such officers may consist of a chairman of the Board of Directors, a Chief Executive Officer, one or more vice-
presidents, secretaries and treasurers and such other officers as may from time to time be considered necessary or expedient. Any number
of offices may be held by the same person.

14.2. The officers shall perform such duties as are prescribed at the time of their appointment subject to any
modification in such duties as may be prescribed thereafter by Resolution of Directors. In the absence of any specific prescription of
duties it shall be the responsibility of the chairman of the Board to preside at meetings of Directors and Members, the Chief Executive
Officer to manage the day to day affairs of the Company, the vice-presidents to act in order of seniority in the absence of the Chief
Executive Officer but otherwise to perform such duties as may be delegated to them by the Chief Executive Officer, the secretaries to
maintain the share register, minute books and records (other than financial records) of the Company and to ensure compliance with all
procedural requirements imposed on the Company by applicable law, and the treasurer to be responsible for the financial affairs of the
Company.

14.3. The emoluments of all officers shall be fixed by Resolution of Directors.

14.4. The officers of the Company shall hold office until their death, resignation or removal. Any officer elected
or appointed by the Directors may be removed at any time, with or without cause, by Resolution of Directors. Any vacancy occurring in
any office of the Company may be filled by Resolution of Directors.

14.5. The Resolution of Directors appointing an agent may authorize the agent to appoint one or more substitutes
or delegates to exercise some or all of the powers conferred on the agent by the Company. The Directors may remove an agent appointed
by the Company and may revoke or vary a power conferred on him.

15. FINANCIAL YEAR

15.1. Unless the Directors otherwise prescribe, the financial year of the Company shall end on 31st December
in each year and, following the year of incorporation, shall begin on 1st January in each year.

16. TRANSFER BY WAY OF CONTINUATION

16.1. The Company may by Resolution of the Directors have the power to register by way of continuation as a
body corporate under the laws of any jurisdiction outside the British Virgin Islands and to be deregistered in the British Virgin Islands.

17. MERGERS AND CONSOLIDATIONS

17.1. The Company shall have the power to merge or consolidate with one or more other constituent companies
upon such terms as the Directors may determine by a Resolution of the Directors subject as may be permitted by the Act.

18. BUSINESS COMBINATION

18.1. Notwithstanding any other Regulations of the Articles, this Regulation 18 shall apply during the period
commencing upon the adoption of the Articles and terminating upon the first to occur of the consummation of any Business Combination and
the distribution of the Trust Fund pursuant to Regulation 18.6. In the event of a conflict between this Regulation 18 and any other Regulation,
the provisions of this Regulation 18 shall prevail, and this Regulation may not be amended prior to the consummation of a Business Combination
without the approval of a Resolution of Members.

18.2. Prior to the consummation of any Business Combination, the Company shall either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) submit such Business Combination to its Members for approval; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) provide Members with the opportunity to have their Shares repurchased by means of a tender offer for an
amount equal to their pro rata share of the Trust Fund, provided that the Company shall not repurchase Shares in an amount that would
cause the Company's net tangible assets to be less than US$5,000,001.

18.3. The Company shall initiate any tender offer in accordance with Rule 13e-4 and Regulation 14E of the Exchange
Act, and shall file tender offer documents with the SEC prior to completing a Business Combination which contain substantially the same
financial and other information about such Business Combination and the redemption rights as is required under Regulation 14A of the Exchange
Act, to repurchase Public Shares.

18.4. At a general meeting called for the purposes of approving a Business Combination pursuant to this Regulation,
in the event that a majority of the Shares voted are voted for the approval of the Business Combination, the Company shall be authorised
to consummate the Business Combination, provided that the Company shall not consummate any Business Combination unless the Company has
net tangible assets of at least US$5,000,001 upon such consummation or any greater net tangible asset or cash requirement that may be
contained in the agreement relating to the Business Combination.

18.5. Any Member holding Shares issued to persons who are not a Founder, officer of the Company or Director
may, contemporaneously with any vote on a Business Combination, elect to have their Public Shares redeemed for cash (the "**IPO Redemption** "), provided that the Member follows the applicable procedures for redemption specified in the applicable disclosure
documents. If so demanded, the Company shall pay any such redeeming Member, regardless of whether he is voting for or against such proposed
Business Combination, a per Share redemption price equal to their pro rata share of the Trust Fund (such redemption price being referred
to herein as the "**Redemption Price** "). The Redemption Price shall be paid promptly following the consummation of the relevant
Business Combination. If the proposed Business Combination is not approved or completed for any reason then such redemptions shall be
cancelled and share certificates (if any) returned to the relevant Members as appropriate.

18.6. (A) The Company shall consummate an initial Business Combination on or before January 23, 2023 (the
 "**Deadline** "), which Deadline may be extended by the Company by Resolution of Directors in up to three (3) separate
 instances (each, an "**Extension**") by an additional one (1) month each, for a total of up to three (3) months (each
 period as extended an "**Extension Period")** without another shareholder vote, provided that if the Company
 exercises the Extension, then the Founders, or their affiliates or designees, shall, upon five (5) days advance notice prior to the
 Deadline, deposit into the Trust Fund, US$0.04 per Public Share outstanding (the "**Top-up Amount**") on or prior to
 the Deadline or the Deadline as extended by any Extension Period validly exercised under this Article 18.6(A).

(B) If the Company does not complete its initial Business Combination on or before the earlier of (i) the Deadline, where no Extension is validly exercised under Article 18.6(A), or (ii) the Deadline, as extended by any Extension Period validly exercised under Article 18.6(A), or (iii) April 23, 2023 (the "**Extended <u>Deadline</u>**"), or if any Top-Up Amount is not paid in full by the Founders as required under Article 18.6(A), the Company shall, as promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding Public Shares for a pro rata portion of the funds held in the Trust Fund, including a pro rata portion of any interest earned, but excluding all expenses paid and reserves for expenses and taxes payable.

18.7. A holder of Public Shares shall be entitled to receive distributions from the Trust Fund only in the event
of an IPO Redemption, a repurchase of Shares by means of a tender offer pursuant to Regulation 18.2(b), or a distribution of the Trust
Fund pursuant to Regulation 18.6. In no other circumstance shall a holder of Public Shares have any right or interest of any kind in the
Trust Fund.

18.8. After the issue of Public Shares, and prior to the consummation of a Business Combination, the Directors
shall not issue additional Shares or any other Securities that participate in any manner in the Trust Fund or that vote as a class with
Public Shares on any Business Combination.

18.9. The uninterested independent Directors shall approve any transaction or transactions between the Company
and any of the following parties:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) any Member owning an interest in the voting power of the Company that gives such Member a significant
influence over the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) any Director or executive officer of the Company and any affiliate or relative of such Director or executive
officer.

18.10. A Director may vote in respect of any Business Combination in which such Director has a conflict of interest
with respect to the evaluation of such Business Combination. Such Director must disclose such interest or conflict to the other Directors.

18.11. The Audit Committee shall monitor compliance with the terms of the IPO and, if any non-compliance is identified,
the Audit Committee shall be charged with the responsibility to take all action necessary to rectify such non-compliance or otherwise
cause compliance with the terms of the IPO.

18.12. The Company may enter into a Business Combination with a target business that is affiliated with the Sponsor,
the Directors or executive officers of the Company and in such event the Company will obtain an opinion from an independent investment
banking or accounting firm that the Business Combination is fair to the Shareholders from a financial point of view.

18.13. The Company will not enter into a Business Combination with a target business that is a blank check company
or a similar company with nominal operations.

19. CONFLICT OF INTERESTS

19.1. A director of the Company shall, forthwith after becoming aware of the fact that he is interested in a
transaction entered into or to be entered into by the Company, disclose the interest to all other Directors.

19.2. For the purposes of Regulation 19.1, a disclosure to all other Directors to the effect that a Director
is a member, director or officer of another named entity or has a fiduciary relationship with respect to the entity or a named individual
and is to be regarded as interested in any transaction which may, after the date of the entry or disclosure, be entered into with that
entity or individual, is a sufficient disclosure of interest in relation to that transaction.

19.3. Subject to any rules or regulations of the Designated Exchange or any laws or regulations governing companies
listed on the Designated Exchange, a Director who is interested in a transaction entered into or to be entered into by the Company may:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) vote on a matter relating to the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) attend a meeting of Directors at which a matter relating to the transaction arises and be included among
the Directors present at the meeting for the purposes of a quorum; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) sign a document on behalf of the Company, or do any other thing in his capacity as a Director, that relates
to the transaction, and, subject to compliance with the Act shall not, by reason of his office be accountable to the Company for any benefit
which he derives from such transaction and no such transaction shall be liable to be avoided on the grounds of any such interest or benefit.

20. INDEMNIFICATION

20.1. Subject to the limitations hereinafter provided the Company shall indemnify against all expenses, including
legal fees, and against all judgments, fines and amounts paid in settlement and reasonably incurred in connection with legal, administrative
or investigative proceedings any person who:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) is or was a party or is threatened to be made a party to any threatened, pending or completed proceedings,
whether civil, criminal, administrative or investigative, by reason of the fact that the person is or was a director of the Company; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) is or was, at the request of the Company, serving as a director of, or in any other capacity is or was
acting for, another company or a partnership, joint venture, trust or other enterprise.

20.2. The indemnity in Regulation 20.1 only applies if the person acted honestly and in good faith with a view
to what that person believed were the best interests of the Company and, in the case of criminal proceedings, the person had no reasonable
cause to believe that their conduct was unlawful.

20.3. The decision of the Directors as to whether the person acted honestly and in good faith and with a view
to the best interests of the Company and as to whether the person had no reasonable cause to believe that his conduct was unlawful is,
in the absence of fraud, sufficient for the purposes of the Articles, unless a question of law is involved.

20.4. The termination of any proceedings by any judgment, order, settlement, conviction or the entering of a *nolle prosequi* does not, by itself, create a presumption that the person did not act honestly and in good faith and with a view
to the best interests of the Company or that the person had reasonable cause to believe that his conduct was unlawful.

20.5. The Company may purchase and maintain insurance in relation to any person who is or was a director, officer
or liquidator of the Company, or who at the request of the Company is or was serving as a director, officer or liquidator of, or in any
other capacity is or was acting for, another company or a partnership, joint venture, trust or other enterprise, against any liability
asserted against the person and incurred by the person in that capacity, whether or not the Company has or would have had the power to
indemnify the person against the liability as provided in the Articles.

21. RECORDS

21.1. The Company shall keep the following documents at the office of its registered agent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Memorandum and the Articles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Register of Members, or a copy of the Register of Members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the register of Directors, or a copy of the register of Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) copies of all notices and other documents filed by the Company with the Registrar of Corporate Affairs
in the previous 10 years.

21.2. If the Company maintains only a single copy of the Register of Members or a copy of the register of Directors
at the office of its registered agent, it shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) within 15 days of any change in either register, notify the registered agent in writing of the change;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) provide the registered agent with a written record of the physical address of the place or places at which
the original Register of Members or the original register of Directors is kept.

21.3. The Company shall keep the following records at the office of its registered agent or at such other place
or places, within or outside the British Virgin Islands, as the Directors may determine:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) minutes of meetings and Resolutions of Members and classes of Members;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) minutes of meetings and Resolutions of Directors and committees of Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) an impression of the Seal, if any.

21.4. Where any original records referred to in this Regulation are maintained other than at the office of the
registered agent of the Company, and the place at which the original records is changed, the Company shall provide the registered agent
with the physical address of the new location of the records of the Company within 14 days of the change of location.

21.5. The records kept by the Company under this Regulation shall be in written form or either wholly or partly
as electronic records.

22. REGISTERS OF CHARGES

22.1. The Company shall maintain at the office of its registered agent a register of charges in which there

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the date of creation of the charge;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) a short description of the liability secured by the charge;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) a short description of the property charged;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the name and address of the trustee for the security or, if there is no such trustee, the name and address
of the chargee;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) unless the charge is a security to bearer, the name and address of the holder of the charge; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) details of any prohibition or restriction contained in the instrument creating the charge on the power
of the Company to create any future charge ranking in priority to or equally with the charge.

23. SEAL

23.1. The Company may have more than one Seal and references herein to the Seal shall be references to every
Seal which shall have been duly adopted by Resolution of Directors. The Directors shall provide for the safe custody of the Seal and for
an imprint thereof to be kept at the registered office. Except as otherwise expressly provided herein the Seal when affixed to any written
instrument shall be witnessed and attested to by the signature of any one director or other person so authorized from time to time by
Resolution of Directors. Such authorization may be before or after the Seal is affixed, may be general or specific and may refer to any
number of sealings. The Directors may provide for a facsimile of the Seal and of the signature of any director or authorized person which
may be reproduced by printing or other means on any instrument and it shall have the same force and validity as if the Seal had been affixed
to such instrument and the same had been attested to as hereinbefore described.

24. ACCOUNTS AND AUDIT

24.1. The Company shall keep records that are sufficient to show and explain the Company's transactions
and that will, at any time, enable the financial position of the Company to be determined with reasonable accuracy.

24.2. The Company may by Resolution of Members call for the Directors to prepare periodically and make available
a profit and loss account and a balance sheet. The profit and loss account and balance sheet shall be drawn up so as to give respectively
a true and fair view of the profit and loss of the Company for a financial period and a true and fair view of the assets and liabilities
of the Company as at the end of a financial period.

24.3. The Company may by Resolution of Members call for the accounts to be examined by auditors.

24.4. The first auditors shall be appointed by Resolution of Directors; subsequent auditors shall be appointed
by a Resolution of Members or a Resolution of Directors.

24.5. The Directors may establish and maintain an audit committee (the "**Audit Committee** ")
as a committee of the Directors and shall adopt a formal written Audit Committee charter and review and assess the adequacy of the formal
written charter on an annual basis. The composition and responsibilities of the Audit Committee shall comply with the rules and regulations
of the SEC and the Designated Stock Exchange. Once formed, the Audit Committee shall meet at least once every financial quarter, or more
frequently as the circumstances dictate.

24.6. The auditors may be Members, but no director or other officer shall be eligible to be an auditor of the
Company during their continuance in office.

24.7. The remuneration of the auditors of the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in the case of auditors appointed by the Directors, may be fixed by Resolution of Directors; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) subject to the foregoing, shall be fixed by Resolution of Members or in such manner as the Company may
by Resolution of Members determine.

24.8. The auditors shall examine each profit and loss account and balance sheet required to be laid before a
meeting of the Members or otherwise given to Members and shall state in a written report whether or not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) in their opinion the profit and loss account and balance sheet give a true and fair view respectively
of the profit and loss for the period covered by the accounts, and of the assets and liabilities of the Company at the end of that period;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all the information and explanations required by the auditors have been obtained.

24.9. The report of the auditors shall be annexed to the accounts and shall be read at the meeting of Members
at which the accounts are laid before the Company or shall be otherwise given to the Members.

24.10. Every auditor of the Company shall have a right of access at all times to the books of account and vouchers
of the Company, and shall be entitled to require from the Directors and officers of the Company such information and explanations as he
thinks necessary for the performance of the duties of the auditors.

24.11. The auditors of the Company shall be entitled to receive notice of, and to attend any meetings of Members
at which the Company's profit and loss account and balance sheet are to be presented.

25. TAX FILINGS

25.1. Each Tax Filing Authorized Person and any such other person, acting alone, as any Director shall designate
from time to time, are authorized to file tax forms SS-4, W-8 BEN, W-8 IMY, W-9, 8832 and 2553 and such other similar tax forms as are
customary to file with any US state or federal governmental authorities or foreign governmental authorities in connection with the formation,
activities and/or elections of the Company and such other tax forms as may be approved from time to time by any Director or officer of
the Company. The Company further ratifies and approves any such filing made by any Tax Filing Authorized Person or such other person prior
to the date of the Articles.

26. NOTICES

26.1. Any notice, information or written statement to be given by the Company to Members may be given by personal
service by mail, facsimile or other similar means of electronic communication, addressed to each Member at the address shown in the share
register.

26.2. Any summons, notice, order, document, process, information or written statement to be served on the Company
may be served by leaving it, or by sending it by registered mail addressed to the Company, at its registered office, or by leaving it
with, or by sending it by registered mail to, the registered agent of the Company.

26.3. Service of any summons, notice, order, document, process, information or written statement to be served
on the Company may be proved by showing that the summons, notice, order, document, process, information or written statement was delivered
to the registered office or the registered agent of the Company or that it was mailed in such time as to admit to its being delivered
to the registered office or the registered agent of the Company in the normal course of delivery within the period prescribed for service
and was correctly addressed and the postage was prepaid.

27. VOLUNTARY WINDING UP

27.1. The Company may by a Resolution of Members or by a Resolution of Directors appoint a voluntary liquidator.

27.2. If the Company does not commence its Business Combination on or before the earlier of (i) the Deadline,
where no Extension is validly exercised under Article 18.6(A), or (ii) the Deadline, as extended by any Extension Period validly exercised
under Article 18.6(A), or (iii) the Extended <u>Deadline</u>, such event shall terminate the existence of the Company and the Company
shall appoint a voluntary liquidator to commence the liquidation of the Company.

We, CONYERS TRUST COMPANY (BVI) LIMITED, registered agent of the Company, of Commerce House, Wickhams Cay 1, PO Box 3140, Road Town, Tortola, British Virgin Islands VG1110 for the purpose of incorporating a BVI Business Company under the laws of the British Virgin Islands hereby sign these Articles of Association on the 24 May 2019.

---

| | |
|:---|:---|
| Incorporator | Incorporator |
| CONYERS TRUST COMPANY (BVI) LIMITED | CONYERS TRUST COMPANY (BVI) LIMITED |
| Per: | Andrew Swapp |
| For and on behalf of | For and on behalf of |
| **Conyers Trust Company (BVI) Limited** | **Conyers Trust Company (BVI) Limited** |

---

## Exhibit 10.1

**Exhibit 10.1**

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "**SECURITIES ACT**"). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

**P R O M I S S O R Y N O T E**

---

| | |
|:---|:---|
| Principal Amount: $21,350 | Dated as of January 20, 2023 |

---

Brilliant Acquisition Corporation, a British Virgin Islands business company (the "**Maker**"), promises to pay to the order of Nukkleus Inc., a Delaware corporation (the "**Payee**") the principal sum of Twenty-One Thousand Three Hundred Fifty Dollars ($21,350) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Promissory Note (this "**Note**") shall be made by check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. **Principal.** The principal balance of this Note shall be payable promptly after the date on which
 the Maker consummates an initial business combination (a "**Business Combination** ")
 with a target business (as described in the Maker's initial public offering prospectus
 dated June 23, 2020 (the "**Prospectus** ")). The principal balance may be
 prepaid at any time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. **Interest.** No interest shall accrue on the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. **Non-Convertible; Non-Recourse**. This Note shall not be convertible into any securities of Maker, and Payee
 shall have no recourse with respect to the Payee's ability to convert this Note into
 any securities of Maker.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. **Application of Payments.** All payments shall be applied first to payment in full of any costs incurred
 in the collection of any sum due under this Note, including (without limitation) reasonable
 attorney's fees, then to the payment in full of any late charges and finally to the
 reduction of the unpaid principal balance of this Note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. **Events of Default.** The following shall constitute an event of default ()"**Event of Default** "):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) **Failure to Make Required Payments.** Failure by Maker to pay the principal of this Note within
 five (5) business days following the date when due.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) **Voluntary Liquidation, Etc.** The commencement by Maker of a proceeding relating to its bankruptcy,
 insolvency, reorganization, rehabilitation or other similar action, or the consent by it
 to the appointment of, or taking possession by, a receiver, liquidator, assignee, trustee,
 custodian, sequestrator (or other similar official) for Maker or for any substantial part
 of its property, or the making by it of any assignment for the benefit of creditors, or the
 failure of Maker generally to pay its debts as such debts become due, or the taking of corporate
 action by Maker in furtherance of any of the foregoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) **Involuntary Bankruptcy, Etc.** The entry of a decree or order for relief by a court having jurisdiction
 in the premises in respect of Maker in an involuntary case under any applicable bankruptcy,
 insolvency or similar law, for the appointing of a receiver, liquidator, assignee, custodian,
 trustee, sequestrator (or similar official) for Maker or for any substantial part of its
 property, or ordering the winding-up or liquidation of the affairs of Maker, and the continuance
 of any such decree or order unstayed and in effect for a period of 60 consecutive days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. **Remedies.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Upon
 the occurrence of an Event of Default specified in Section 5(a) hereof, the Payee may, by
 written notice to Maker, declare this Note to be due immediately and payable, whereupon the
 unpaid principal amount of this Note, and all other amounts payable hereunder, shall become
 immediately due and payable without presentment, demand, protest or other notice of any kind,
 all of which are hereby expressly waived, anything contained herein or in the documents evidencing
 the same to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Upon
 the occurrence of an Event of Default specified in Sections 5(b) and 5(c), the unpaid principal
 balance of this Note, and all other sums payable with regard to this Note, shall automatically
 and immediately become due and payable, in all cases without any action on the part of the
 Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. **Waivers.** Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment
 for payment, demand, notice of dishonor, protest, and notice of protest with regard to the
 Note, all errors, defects and imperfections in any proceedings instituted by the Payee under
 the terms of this Note, and all benefits that might accrue to Maker by virtue of any present
 or future laws exempting any property, real or personal, or any part of the proceeds arising
 from any sale of any such property, from attachment, levy or sale under execution, or providing
 for any stay of execution, exemption from civil process, or extension of time for payment;
 and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained
 by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ
 in whole or in part in any order desired by the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. **Unconditional Liability.** Maker hereby waives all notices in connection with the delivery, acceptance,
 performance, default, or enforcement of the payment of this Note, and agrees that its liability
 shall be unconditional, without regard to the liability of any other party, and shall not
 be affected in any manner by any indulgence, extension of time, renewal, waiver or modification
 granted or consented to by the Payee, and consents to any and all extensions of time, renewals,
 waivers, or modifications that may be granted by the Payee with respect to the payment or
 other provisions of this Note, and agrees that additional makers, endorsers, guarantors,
 or sureties may become parties hereto without notice to Maker or affecting Maker's
 liability hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. **Notices.** Any notice called for hereunder shall be deemed properly given if (i) sent by certified
 mail, return receipt requested, (ii) personally delivered, (iii) dispatched by any form of
 private or governmental express mail or delivery service providing receipted delivery or
 (iv) sent by facsimile or (v) to the following addresses or to such other address as either
 party may designate by notice in accordance with this Section:

If to Maker:

<br> Brilliant Acquisition Corporation

99 Dan Ba Road, C-9, Putuo District,

Shanghai, Peoples Republic of China 200062

If to Payee:

Nukkleus Inc.<br> 525 Washington Blvd.

Jersey City, New Jersey 07310

Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the date shown on a facsimile transmission confirmation, (iii) the date reflected on a signed delivery receipt, or (iv) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. **Construction.** THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
 NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW PROVISIONS THEREOF.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. **Jurisdiction.** The courts of the State of New York have exclusive jurisdiction to settle any dispute
 arising out of or in connection with this agreement (including a dispute relating to any
 non-contractual obligations arising out of or in connection with this agreement) and the
 parties submit to the exclusive jurisdiction of the courts of New York.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. **Severability.** Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction
 shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability
 without invalidating the remaining provisions hereof, and any such prohibition or unenforceability
 in any jurisdiction shall not invalidate or render unenforceable such provision in any other
 jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. **Trust Waiver.** The Payee has been provided a copy of the Prospectus. Notwithstanding anything
 herein to the contrary, the Payee hereby waives any and all right, title, interest or claim
 of any kind ()"**Claim**") in or to any amounts contained in the trust account
 in which the proceeds of the initial public offering (the "**IPO**") conducted
 by the Maker and the proceeds of the sale of securities in a private placement that occurred
 prior to the effectiveness of the IPO, as described in greater detail in the Prospectus,
 were placed, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction
 for any Claim from the trust account or any distribution therefrom for any reason whatsoever.
 If Maker does not consummate a Business Combination, this Note shall be repaid only from
 amounts remaining outside of the trust account, if any.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. **Amendment; Waiver.** Any amendment hereto or waiver of any provision hereof may be made with, and
 only with, the written consent of the Maker and the Payee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. **Assignment.** No assignment or transfer of this Note or any rights or obligations hereunder may be
 made by any party hereto (by operation of law or otherwise) without the prior written consent
 of the other party hereto and any attempted assignment without the required consent shall
 be void.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. **Further Assurance.** The Maker shall, at its own cost and expense, execute and do (or procure to
 be executed and done by any other necessary party) all such deeds, documents, acts and things
 as the Payee may from time to time require as may be necessary to give full effect to this
 Note.

 

*[The rest of this page is intentionally left blank]*

IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed on the day and year first above written.

---

| | | |
|:---|:---|:---|
| BRILLIANT ACQUISITION CORPORATION | BRILLIANT ACQUISITION CORPORATION | BRILLIANT ACQUISITION CORPORATION |
| By: | /s/ Peng Jiang | /s/ Peng Jiang |
|  | Name: | Peng Jiang |
|  | Title: | Chairman and CEO |

---

Accepted and Agreed:

---

| | | |
|:---|:---|:---|
| NUKKLEUS INC. | NUKKLEUS INC. | NUKKLEUS INC. |
| By: | /s/ Emil Assentato | /s/ Emil Assentato |
|  | Name: | Emil Assentato |
|  | Title: | President and Chief Executive Officer |

---

*[Signature Page to Promissory Note]*

## Exhibit 99.1

**Exhibit 99.1**

**Brilliant Acquisition Corporation Announces Extension of Completion Window to February 23, 2023**

**January 24, 2023 \| Source: Brilliant Acquisition Corporation**

New York, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Brilliant Acquisition Corporation ("Brilliant") announced today that it has extended the period of time it will have to consummate its initial business combination by a further one month, or until February 23, 2023. In connection with the extension, Nukkleus, Inc. ("Nukkleus") has deposited $21,350 in Brilliant's trust account, representing $0.0525 per public ordinary share of Brilliant currently outstanding, as additional interest on the proceeds in the trust account. The extension was approved by Brilliant's shareholders on January 19, 2023. The shareholder approval also permits Brilliant to further extend Brilliant's initial business combination deadline on a monthly basis up to a further two months, or until April 23, 2023. Nukkleus will deposit an additional $32,500 in the trust account for any such additional monthly extension, representing $0.08 per public ordinary share of Brilliant outstanding.

The purpose of the extension is to permit sufficient time for Brilliant to consummate its previously announced proposed business combination with Nukkleus. For a summary of the material terms of the proposed business combination, please see Brilliant's Current Report on Form 8-K filed on February 23, 2022 and Nukkleus's Registration Statement on Form S-4 initially filed on April 15, 2022 (as amended to date), with the U.S. Securities and Exchange Commission (the "SEC") in connection with the announcement of the proposed business combination.

**About Brilliant Acquisition Corp.**

Brilliant (Nasdaq: BRLI) is a blank check company organized for the purpose of effecting a merger, share exchange, asset acquisition, or other similar business combination with one or more businesses or entities.

**Additional Information and Where to Find It**

This press release relates to a proposed business combination transaction between Nukkleus and Brilliant pursuant to which Nukkleus will become the parent company of Brilliant upon the closing of the transactions. In connection with the proposed transaction, Nukkleus has filed with the SEC a Registration Statement on Form S-4, including a proxy statement (the "proxy statement"). The definitive proxy statement (if and when available) will be delivered to Nukkleus's and Brilliant's shareholders. Each of Nukkleus and Brilliant may also file other relevant documents regarding the proposed transaction with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS OF NUKKLEUS AND BRILLIANT ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS THAT ARE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED TRANSACTION, INCLUDING ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION.

Investors and security holders may obtain free copies of the proxy statement (if and when available) and other documents that are filed or will be filed with the SEC by Nukkleus or Brilliant through the website maintained by the SEC at www.sec.gov. Stockholders of Nukkleus will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Nukkleus, Inc., 525 Washington Boulevard, Jersey City, New Jersey 07310. Shareholders of Brilliant will also be able to obtain a copy of the definitive proxy statement, without charge by directing a request to: Brilliant Acquisition Corporation, 99 Dan Ba Road, C-9, Putuo District, Shanghai, Peoples Republic of China.

**Participants in the Solicitation**

Nukkleus and its directors and executive officers are participants in the solicitation of proxies from the stockholders of Nukkleus in respect of the proposed transaction. Information about Nukkleus's directors and executive officers and their ownership of Nukkleus common stock is set forth in Nukkleus's Annual Report on Form 10-K for the year ended September 30, 2021, filed with the SEC on December 29, 2021. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described in the preceding paragraph.

Brilliant and its directors and executive officers are participants in the solicitation of proxies from the shareholders of Brilliant in respect of the proposed transaction. Information about Brilliant's directors and executive officers and their ownership of Brilliant's ordinary shares is set forth in Brilliant's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available. You may obtain free copies of these documents as described above.

**Forward Looking Statements**

This press release includes forward-looking statements that involve risks and uncertainties. Forward looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Brilliant expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Brilliant's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

**Contact:**

Dr. Peng Jiang<br> Chief Executive Officer<br> Brilliant Acquisition Corporation<br> + (86) 021-80125497